{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-22-000035","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2022-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.408163+00:00","generated_at":"2026-06-26T23:20:26.561385+00:00","sec_items":["2.02","4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sema4 reports Q4 revenue $57.8M, restates prior-period financials due to expense classification errors","bullets":["Q4 2021 revenue $57.8M (up 24% ex-COVID); full-year revenue $212.2M. Net loss $40.2M Q4, $245.4M full year.","Test volumes (ex-COVID) grew 37% YoY to 82,966; Oncology volumes up 142%, Women's Health up 33%.","Restating audited financials for 2020 and 2019, and unaudited quarters in 2021/2020, due to expense misclassification and out-of-period cost recognition.","2022 guidance: total revenue $215-225M, test volume growth >20% ex-COVID, adjusted gross margin >10%; excludes pending GeneDx acquisition.","Cash $400.6M at Dec 31, 2021; pending $200M PIPE and GeneDx acquisition expected to close Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-22-000035","json":"https://secwatch.observer/filing/0001818331-22-000035.json","markdown":"https://secwatch.observer/filing/0001818331-22-000035.md","text":"https://secwatch.observer/filing/0001818331-22-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/0001818331-22-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/smfr-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:20:26.561385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}